Lovaza Manufacturer to Enter Consumer Healthcare Market

Article

Pronova BioPharma (Lysaker, Norway) says it will enter the consumer healthcare market during the second half of 2012.

Answering to rising consumer interest in omega-3 products, Pronova BioPharma (Lysaker, Norway) says it will enter the consumer healthcare market during the second half of 2012. The company currently markets Omacor/Lovaza, the only omega-3 pharmaceutical drug approved for use by FDA and the EU.

Over the next 12 months, Pronova plans to build its consumer healthcare division by initiating clinical trials, adjusting manufacturing its manufacturing process for consumer products, and developing distribution channels.

Related Videos
Nils Hoem and Nutritional Outlook editor Sebastian Krawiec
Related Content
© 2024 MJH Life Sciences

All rights reserved.